Compare Stocks: ONCY, LXEO, UPB, and CAPR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$7.39 +17.5%	$16.33	$2.96 ▼ $40.37	$430.24M	0.54	2.75 million shs	10.67 million shs
LXEO Lexeo Therapeutics	$4.92 +0.8%	$4.73	$3.99 ▼ $10.99	$402.03M	1.46	945,722 shs	123,685 shs
ONCY Oncolytics Biotech	$0.83 -2.1%	$0.86	$0.73 ▼ $1.51	$105.20M	1.13	1.29 million shs	168,097 shs
UPB Upstream Bio	$6.60 -5.4%	$6.87	$5.85 ▼ $33.68	$361.21M	1.26	864,492 shs	85,803 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	0.00%	-5.41%	-68.07%	-78.21%	-11.41%
LXEO Lexeo Therapeutics	0.00%	+0.83%	+4.72%	-4.50%	-0.41%
ONCY Oncolytics Biotech	0.00%	+1.09%	+3.80%	+4.15%	-16.52%
UPB Upstream Bio	0.00%	-1.41%	+8.74%	-16.73%	-60.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$7.39 +17.5%	$16.33	$2.96 ▼ $40.37	$430.24M	0.54	2.75 million shs	10.67 million shs
LXEO Lexeo Therapeutics	$4.92 +0.8%	$4.73	$3.99 ▼ $10.99	$402.03M	1.46	945,722 shs	123,685 shs
ONCY Oncolytics Biotech	$0.83 -2.1%	$0.86	$0.73 ▼ $1.51	$105.20M	1.13	1.29 million shs	168,097 shs
UPB Upstream Bio	$6.60 -5.4%	$6.87	$5.85 ▼ $33.68	$361.21M	1.26	864,492 shs	85,803 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	0.00%	-5.41%	-68.07%	-78.21%	-11.41%
LXEO Lexeo Therapeutics	0.00%	+0.83%	+4.72%	-4.50%	-0.41%
ONCY Oncolytics Biotech	0.00%	+1.09%	+3.80%	+4.15%	-16.52%
UPB Upstream Bio	0.00%	-1.41%	+8.74%	-16.73%	-60.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	2.00	Hold	$29.15	294.56% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$18.75	281.25% Upside
ONCY Oncolytics Biotech	2.67	Moderate Buy	$5.00	506.06% Upside
UPB Upstream Bio	2.43	Hold	$29.67	349.84% Upside

Current Analyst Ratings Breakdown

Latest ONCY, LXEO, UPB, and CAPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
8/17/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/14/2026	UPB Upstream Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$8.00 ➝ $9.00
8/13/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	UPB Upstream Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00
8/3/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/31/2026	CAPR Capricor Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$2.00
7/30/2026	CAPR Capricor Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$22.27M	19.29	N/A	N/A	$5.53 per share	1.34
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.38 per share	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	($0.04) per share	N/A
UPB Upstream Bio	$2.85M	126.74	N/A	N/A	$6.29 per share	1.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
LXEO Lexeo Therapeutics	-$99.96M	-$1.15	N/A	N/A	N/A	N/A	-41.85%	-38.03%	N/A
ONCY Oncolytics Biotech	-$28.76M	-$0.34	N/A	N/A	N/A	N/A	-2,185.97%	-442.99%	11/11/2026 (Estimated)
UPB Upstream Bio	-$143.44M	-$2.90	N/A	N/A	N/A	-4,955.67%	-48.40%	-46.57%	11/4/2026 (Estimated)

Latest ONCY, LXEO, UPB, and CAPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/12/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.2852	-$0.30	-$0.0148	-$0.30	N/A	N/A
8/12/2026	Q2 2026	ONCY Oncolytics Biotech	-$0.0538	-$0.08	-$0.0262	-$0.08	N/A	N/A
8/11/2026	Q2 2026	UPB Upstream Bio	-$0.7444	-$0.73	+$0.0144	-$0.73	$0.56 million	$0.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	7.35	7.35
LXEO Lexeo Therapeutics	N/A	13.89	13.89
ONCY Oncolytics Biotech	N/A	1.35	1.35
UPB Upstream Bio	N/A	27.99	27.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
LXEO Lexeo Therapeutics	60.67%
ONCY Oncolytics Biotech	6.82%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	9.20%
LXEO Lexeo Therapeutics	2.00%
ONCY Oncolytics Biotech	0.10%
UPB Upstream Bio	16.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	101	58.14 million	52.79 million	Optionable
LXEO Lexeo Therapeutics	58	82.05 million	80.41 million	Not Optionable
ONCY Oncolytics Biotech	30	127.51 million	127.38 million	Not Optionable
UPB Upstream Bio	38	54.77 million	45.76 million	N/A

ONCY, LXEO, UPB, and CAPR Headlines

Recent News About These Companies

Upstream Bio (NASDAQ:UPB) Price Target Raised to $9.00

August 17, 2026 | americanbankingnews.com

Upstream Bio Inc (UPB)

August 16, 2026 | investing.com

Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB

August 15, 2026 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Cut to "Strong Sell" at Wall Street Zen

August 15, 2026 | americanbankingnews.com

Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen

August 15, 2026 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co.

August 14, 2026 | marketbeat.com

Q3 EPS Estimates for Upstream Bio Decreased by HC Wainwright

August 14, 2026 | marketbeat.com

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

August 11, 2026 | markets.businessinsider.com

Upstream Bio (NASDAQ:UPB) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS

August 11, 2026 | marketbeat.com

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

August 11, 2026 | zacks.com

Arrowstreet Capital Limited Partnership Buys New Holdings in Upstream Bio, Inc. $UPB

August 6, 2026 | marketbeat.com

Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Hold" from Analysts

July 31, 2026 | marketbeat.com

Upstream Bio (UPB) Expected to Release Quarterly Earnings on Wednesday

July 29, 2026 | marketbeat.com

Altshuler Shaham Ltd Reduces Position in Upstream Bio, Inc. $UPB

July 29, 2026 | marketbeat.com

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

July 14, 2026 | zacks.com

Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?

June 25, 2026 | insidermonkey.com

10 small-cap U.S. healthcare stocks with the weakest momentum grades

June 24, 2026 | seekingalpha.com

Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?

June 23, 2026 | insidermonkey.com

Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients

June 19, 2026 | businesswire.com

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the ...

June 14, 2026 | markets.businessinsider.com

Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms

June 14, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, LXEO, UPB, and CAPR Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

$7.39 +1.10 (+17.46%)

As of 11:13 AM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Lexeo Therapeutics NASDAQ:LXEO

$4.92 +0.04 (+0.78%)

As of 11:13 AM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Oncolytics Biotech NASDAQ:ONCY

$0.82 -0.02 (-2.15%)

As of 11:13 AM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Upstream Bio NASDAQ:UPB

$6.60 -0.38 (-5.38%)

As of 11:13 AM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ONCY, LXEO, UPB, and CAPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ONCY, LXEO, UPB, and CAPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ONCY, LXEO, UPB, and CAPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, LXEO, UPB, and CAPR Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

Lexeo Therapeutics NASDAQ:LXEO

Oncolytics Biotech NASDAQ:ONCY

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ONCY, LXEO, UPB, and CAPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ONCY, LXEO, UPB, and CAPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ONCY, LXEO, UPB, and CAPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, LXEO, UPB, and CAPR Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

Lexeo Therapeutics NASDAQ:LXEO

Oncolytics Biotech NASDAQ:ONCY

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools